Rupatadine added to mesalamine for ulcerative colitis
Official title: Clinical Study to Evaluate Safety and Efficacy of Rupatadine in Patients With Ulcerative Colitis.
Run by Alexandria University · NCT07064707 · Data updated 2026-11-12
This trial will test whether adding rupatadine to standard mesalamine improves symptoms and inflammation in adults with mild-to-moderate ulcerative colitis.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Alexandria University Academic / other |
| Locations | 1 site (Alexandria) |
| Status | Recruiting |
| Started | July 15, 2025 |
| Main results expected | July 15, 2026 |
| Study ends | October 21, 2026 |
| Registry record updated | November 19, 2025 |
| Trial ID | NCT07064707 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with endoscopy- and biopsy-confirmed mild-to-moderate ulcerative colitis who are not pregnant or breastfeeding and are not taking systemic steroids, immunosuppressives, or biologic therapies are the intended participants.
✕Probably not a fit
Patients with severe ulcerative colitis, those on systemic steroids, immunosuppressives, or biologic treatments, pregnant or breastfeeding people, colorectal cancer patients, or anyone allergic to the study drugs are excluded and unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a Phase 2 interventional trial testing rupatadine given alongside mesalamine in adults with mild-to-moderate ulcerative colitis confirmed by endoscopy and histopathology. Eligible participants are aged 18 or older and must not be receiving systemic steroids, immunosuppressives, or biologic therapies. Pregnant or breastfeeding individuals, patients with severe UC, colorectal cancer, or known allergy to the study medications are excluded. The registry summary does not specify randomization or blinding details, and efficacy endpoints are not provided in the brief listing.
Why it matters
Potential benefit: If successful, rupatadine could provide a well-tolerated oral add-on that reduces inflammation and symptoms for patients with mild-to-moderate UC.
How similar studies have gone: Applying rupatadine to ulcerative colitis is a novel approach with limited prior clinical evidence, though antihistamine and platelet-activating-factor–targeting strategies have been explored preclinically.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion criteria: * Age ≥ 18 years * Both male and female will be included * Mild and moderate UC patients are already diagnosed and confirmed by endoscope and histopathology. Exclusion criteria: * Breast feeding or pregnancy. * Colorectal cancer patients. * Patients with severe UC. * Patients taking rectal or systemic steroids. * Patients taking immunosuppressives or biological therapies. * Addiction to alcohol and / or drugs. * Known allergy to the studied medications.
Where it's running
-
Alexandria University
Alexandria, Egypt Recruiting
Study contacts
- Study coordinator: Reham Elshafiey, PhD
- Email: rehamelshafiey@gmail.com
- Phone: 01025465180
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Innovative Multidisciplinary and Virtual Care for IBD in Pregnancy
This study tests a dedicated IBD pregnancy care model, including a new virtual approach, to see if it improves access and quality of care for pregnant people with Crohn's disease or ulcerative colitis.
-
A Probiotic Approach to Modulating Gut Microbiota in Mild-to-Moderate Ulcerative Colitis
A specific probiotic given rectally will be tested in adults with mild-to-moderate ulcerative colitis to see if it can help manage symptoms.
-
Advanced therapies for moderately to severely active Crohn's disease or ulcerative colitis in adults
This study tests combinations of risankizumab with either trosunilimab or ABBV-701 in adults with moderately to severely active Crohn's disease or ulcerative colitis.
-
Longitudinal Immunophenotyping of People with Inflammatory Bowel Disease
This study will follow adults with Crohn's disease or ulcerative colitis (and some healthy relatives) over three years to see how their immune cells change over time and how genetics and diet relate to their disease.
-
High Protein, High Fiber Diet for Ulcerative Colitis
This study tests a high-protein, high-fiber diet to see if it helps people with ulcerative colitis by meeting protein needs and lowering harmful hydrogen sulfide production in the gut.
-
Ath-063: Testing a new treatment for moderately to severely active ulcerative colitis in patients who have tried other biologics
This study tests ATH-063 to see if it helps people with moderate to severe ulcerative colitis who did not respond to or relapsed after prior biologic therapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.